Takeda Ventures converted debt financing into equity through the genetic medicine developer's latest round, which was led by strategic partner AnGes.

Biopharmaceutical company AnGes led a $61m series B round for US-based gene-editing technology developer Emendo Biotherapeutics on Wednesday. The round included an undisclosed amount of convertible note financing provided by pharmaceutical firm Takeda‚Äôs investment arm, Takeda Ventures, in April 2019 which was converted to equity. Healthcare investment firm OrbiMed also invested, as did its OrbiMed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.